1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On June 22, 2026, SolarMax Technology received a Nasdaq notice that it does not meet the Nasdaq Capital Market requirement to maintain at least $35 million in market value of listed securities. The company has 180 calendar days, until December 21, 2026, to regain compliance, and this notice is in addition to an earlier Nasdaq notice about its $1.00 minimum bid price. If the company does not regain compliance by then, it will receive written notice that its securities are subject to delisting.
Nasdaq notice dated June 22, 2026, cites Rule 5550(b)(2), the $35 million minimum market value of listed securities.
Compliance period runs 180 calendar days and expires December 21, 2026.
Regaining compliance requires market value of at least $35 million for a minimum of ten consecutive business days.
Separate from the previously announced Nasdaq notice for failing the $1.00 minimum bid price.
Monopar Therapeutics said the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline), its late-stage candidate for Wilson disease. The designation gives the company the potential to receive a pediatric Priority Review Voucher if the drug is approved, but the filing does not say whether approval will come or whether a voucher will be awarded.
FDA granted Rare Pediatric Disease designation to ALXN1840 for Wilson disease, announced June 30, 2026
The designation provides potential eligibility for a pediatric Priority Review Voucher at the time of NDA approval
The filing does not report revenue, earnings, or guidance
Larimar Therapeutics said it has submitted the first module of a rolling Biologics License Application to the FDA for accelerated approval of nomlabofusp, after FDA meeting minutes said the existing data package appears sufficient for submission. The company also reported longer-term open label data, which showed improvements in some clinical measures alongside anaphylaxis in 10 of 43 patients, a safety finding shareholders should weigh.
First module of the rolling BLA submitted; remaining modules expected in the second half of 2026.
FDA meeting minutes say the existing data package appears sufficient for a BLA seeking accelerated approval; approval will be a matter of review.
Anaphylaxis occurred in 10 of 43 patients in the open label study, 9 of whom had prior exposure to nomlabofusp.
At 1 year, 100% (9/9) of participants had skin FXN levels above 50% of healthy volunteer mean; first patient dosing in a global Phase 3 study is expected in Q3 2026.
Atlas Lithium said the Minas Gerais permitting commission voted on June 26, 2026 to grant its expansion permit, applied for on November 25, 2024, and the decision was published in the state gazette on June 27, 2026. The permit covers additional mining areas and authorizes assembling and operating its lithium processing plant, processing mined ore there, and selling the lithium concentrate it produces, which the company says positions it to advance its Neves Project.
Permitting commission vote granting the expansion permit: June 26, 2026
Official gazette publication in Minas Gerais, Brazil: June 27, 2026
Permit covers additional mining areas beyond those in the operational permit received October 25, 2024
Permit authorizes plant assembly and operation, ore processing, and sale of lithium concentrate
Ark Restaurants said a New York court on June 18, 2026 granted it summary judgment on its breach of contract claim over the Bryant Park Grill lease and the related right of first lease for the Bryant Park Café, with money damages to be set at a later trial. The court also ruled against the company on ejectment and use and occupancy claims for the Café and The Porch, and the company says it will appeal the adverse portions, which would automatically stay eviction while the appeal is pending. The company says the dispute has had and is expected to continue to have a material adverse impact on its business and results.
June 18, 2026: court granted Ark summary judgment on breach of contract for the Bryant Park Grill lease and related right of first lease for the Bryant Park Café
Court did not grant specific performance and did not preclude the Landlord's ejectment claim; damages for the Grill to be determined at a future trial
Court ruled for the Landlord on ejectment, use and occupancy, and breach of contract for the Café and The Porch; the Landlord may seek use and occupancy damages at trial
Company intends to file a Notice of Appeal, which would stay eviction pending appeal; the court will set the amount of the required undertaking
American Express announced the results of its company-run 2026 Dodd-Frank Act Stress Test and said its Stress Capital Buffer requirement stays at 2.5 percent through September 30, 2027, in line with the Federal Reserve's February 4, 2026 announcement. The company said the results reflect the strength of its balance sheet and that it will continue returning capital to shareholders.
Stress Capital Buffer requirement remains at 2.5 percent, the minimum under applicable regulations, through September 30, 2027
Quarterly common share dividend increased 16 percent to $0.95 per share beginning with the first-quarter 2026 declaration
American Express returned $8.7 billion to shareholders via buybacks and dividends in the 12 months ended March 31, 2026
NANO Nuclear reported that the U.S. Nuclear Regulatory Commission has started formal review activities for the construction permit application for its KRONOS MMR reactor at the University of Illinois Urbana-Champaign. The filing says the NRC's projected schedule is consistent with the company's earlier expectation that the review could finish in 2027, with initial construction possible in the second half of 2027.
NRC publicly announced on June 23, 2026 that it met with the University of Illinois and NANO Nuclear to start the review.
NRC accepted the construction permit application for review on May 18, 2026.
NRC expects the environmental assessment in Spring 2027 and the safety evaluation in early Fall 2027.
Company says initial construction on campus could begin in the second half of 2027, subject to regulatory approvals.
JPMorgan Chase released its 2026 Dodd-Frank Act stress test results on June 24, 2026, based on the Federal Reserve's hypothetical Supervisory Severely Adverse Scenario. The projections show the firm's common equity tier 1 (CET1) ratio falling from 14.6% at the end of 4Q25 to a projected minimum of 12.4%, ending at 14.4% in 1Q28, and $70.2 billion of projected loan losses over nine quarters. The company states that these are hypothetical estimates, not forecasts of actual results.
Projected minimum CET1 ratio of 12.4%, versus 14.6% actual at 4Q25 and a 4.5% regulatory minimum
Nine-quarter projected pre-provision net revenue of $135.9 billion and provision for credit losses of $95.6 billion (1Q26 to 1Q28)
Projected net income before taxes of $11.4 billion and total projected loan losses of $70.2 billion
JPMorgan Chase Bank, N.A. projected minimum CET1 ratio of 13.2%
The Fund's Board of Trustees approved changes to its 80% investment policy on June 23, 2026, effective August 28, 2026. The policy now covers corporate debt obligations and income-producing investments, which may include those of non-corporate issuers, and the filing describes which instruments count as income-producing.
Board approved the policy change on June 23, 2026; effective date is August 28, 2026.
Fund invests at least 80% of net assets (plus borrowings for investment purposes) in corporate debt obligations and/or income-producing investments.
Fund may not change the 80% Policy without at least 60 days' written notice to shareholders.
Supplement dated June 24, 2026 updates the prospectus and statement of additional information (Exhibit 99.1).
Chemours agreed on June 23, 2026 to a proposed Consent Decree with the U.S. EPA and the West Virginia Department of Environmental Protection to resolve claims over PFAS emissions and other alleged activities at its Washington Works, Fayetteville Works and Chambers Works facilities. The settlement remains subject to court approval, and the company says it expects the expansion of its off-site drinking water programs to increase its existing environmental reserves, which could weigh on future results.
Civil penalty of $22.5 million, payable in three annual installments; $15 million was previously accrued
$90 million to fund additional PFAS mitigation projects or drinking water relief over the next 15 years
Separate resolution of West Virginia Rivers Coalition Clean Water Act suit from 2024 for less than $1 million
Settlement is subject to notice, comment and court approval and is not an admission of liability
Smith Micro Software received written notice from Nasdaq on June 23, 2026 that its common stock closed at or above $1.00 for 10 consecutive business days, from June 8 to June 22, 2026. The company has therefore regained compliance with Nasdaq's minimum bid price requirement and the matter is closed, removing the risk of delisting over the low share price.
Nasdaq notified the company on June 23, 2026 that it regained compliance with the $1.00 minimum bid price requirement.
Compliance was based on closing prices at or above $1.00 for 10 consecutive business days, June 8 to June 22, 2026.
The compliance period had been extended to June 22, 2026 after an initial deadline of December 22, 2025.
Office Properties Income Trust (OPI) emerged from chapter 11 on June 17, 2026, and RMR LLC, RMR Group's majority-owned subsidiary, entered into amended business and property management agreements with OPI. The filing sets a five-year initial term, a $14.0 million annual business management fee for the first two years, and equity issuances to RMR LLC that could reach 10% of OPI's common equity.
OPI's Plan became effective June 17, 2026, after confirmation by the Bankruptcy Court on April 22, 2026.
Amended business management agreement pays RMR LLC $14.0 million a year for the first two years.
RMR LLC receives OPI common shares equal to 2% of common equity on the Effective Date, plus up to 8% more upon meeting metrics set by OPI's board.
AeroVironment said its previously issued financial statements for the three and nine months ended January 31, 2026 require restatement after an error in the goodwill impairment analysis for its Space reporting unit. The restated figures show a larger net loss and loss from operations, and management found a newly identified material weakness in internal control over financial reporting. Separately, directors David Wodlinger and Henry Albers resigned from the Board effective June 17, 2026, leaving the Board with eight directors.
Net loss was understated by $87,272,000 for the three and nine months ended January 31, 2026; loss from operations was understated by $89,402,000.
Basic and diluted net loss per share was understated by $1.75 for the three months and $1.79 for the nine months ended January 31, 2026.
Management identified a material weakness in controls over the goodwill impairment analysis and concluded disclosure controls were ineffective as of January 31, 2026.
Directors David Wodlinger and Henry Albers resigned effective June 17, 2026; the Arlington Capital shareholder may designate two successors, and none had been designated as of the filing date.
Actinium Pharmaceuticals submitted a compliance plan to NYSE American on June 18, 2026, describing actions management intends to take to restore compliance with listing standards. The exchange had notified the company on May 27, 2026 that its stockholders' equity was below the $4.0 million minimum required under Section 1003(a)(ii) of the NYSE American Company Guide, which applies after losses in three of four recent fiscal years.
June 18, 2026: Company submitted its compliance plan to NYSE American.
May 27, 2026: Company received the NYSE American notice regarding stockholders' equity.
Required minimum: stockholders' equity of $4.0 million or more under Section 1003(a)(ii).
The filing does not specify the individual actions management plans to take.
GRI Bio said on June 18, 2026 that the U.S. Food and Drug Administration granted Orphan Drug Designation to GRI-0621, its oral investigational therapy for idiopathic pulmonary fibrosis (IPF). The designation provides potential benefits such as seven years of U.S. market exclusivity upon approval, but the filing does not report revenue, earnings, or changes to guidance.
FDA granted Orphan Drug Designation to GRI-0621 for IPF, announced June 18, 2026
Orphan designation applies to diseases affecting fewer than 200,000 people in the U.S.; benefits include potential seven years of U.S. market exclusivity upon approval
GRI-0621 was evaluated in a 35-patient Phase 2a trial (GRI-0621-IPF-02), which the company says met its primary, secondary and exploratory endpoints
Otter Tail's subsidiaries Northern Pipe Products and Vinyltech agreed on June 17, 2026 to pay $30 million into a settlement fund to resolve end-user class claims in the PVC Pipe Antitrust Litigation. The settlement requires court approval, and the company says it will use available cash and does not expect a material adverse effect on its financial position or liquidity.
Settlement amount: $30 million, paid into a fund after preliminary court approval, with payment due about 21 days after that approval.
Settlement covers End-User Class claims in In re: PVC Pipe Antitrust Litigation (Case No. 1:24-cv-07639), U.S. District Court for the Northern District of Illinois.
The company does not admit wrongdoing and says it will keep defending itself if the settlement is not finalized.
The filing says the settlement is not expected to have a material adverse effect on financial position or liquidity.
Gencor Industries received a NYSE American notice on May 19, 2026, for failing to timely file its quarterly report for the period ended March 31, 2026. The company filed that Form 10-Q on June 12, 2026, and on June 15, 2026, the NYSE said Gencor had regained compliance and would be removed from its late filers' list. The matter is resolved, so no delisting is pending based on this filing.
NYSE American delinquency notice received May 19, 2026, for late Form 10-Q for the period ended March 31, 2026
Form 10-Q filed June 12, 2026, within the six-month compliance period
NYSE notified Gencor on June 15, 2026, that it regained compliance with Section 1007 of the NYSE American Company Guide
MaxCyte received a Nasdaq letter on June 10, 2026 stating that its common stock closed at $1.00 or above for the last 10 consecutive business days, from May 27 to June 9, 2026. Nasdaq closed the matter, and the company says it has regained compliance with the minimum bid price rule. This removes the bid price deficiency that Nasdaq had flagged in March 2026.
Nasdaq notice on March 16, 2026 cited a closing bid price below $1.00 for 30 consecutive trading days
Nasdaq letter dated June 10, 2026 confirmed the closing bid price was at $1.00 or greater from May 27 to June 9, 2026
Nasdaq closed the matter under Listing Rule 5450(a)(1)
South Korea's Personal Information Protection Commission announced fines totaling about $410 million against Coupang Corp., a Korean subsidiary, one tied to the November 2025 data incident and one tied to a third-party advertising data program. Coupang says it will recognize these fines in its 2026 second quarter operating results and will seek judicial relief, though final amounts and corrective measures may change once formal decisions are issued.
PIPC announced fines of about $278 million related to the November 2025 data incident and about $132 million for a separate advertising data matter, announced June 10, 2026
Estimated fines of about $410 million will be recorded in 2026 second quarter operating, general and administrative expenses
Fines are not automatically stayed during appeal and are not tax deductible; Coupang Corp. will pursue relief in the Seoul Administrative Court
On June 2, 2026, an arbitration panel issued a final award in a dispute between subsidiary Maiden Reinsurance Ltd. and a ceding company. The panel denied the request to rescind the reinsurance agreement, but unanimously found the ceding company committed an intentional and material breach, and the award requires adjustments that include repayment of part of the approximately $10.8 million previously paid. The amount and timing of any net financial statement impact have not yet been determined.
Final Award dated June 2, 2026; by majority, the panel denied rescission, and attachment points and limits remain unchanged.
The panel unanimously found the Cedant made an intentional and material breach by changing its reserving or claims methods without the reinsurer's consent.
The subsidiary previously paid $10.8 million in net losses and may have to repay part of that amount.
The subsidiary was awarded $1.0 million in attorneys' fees; as of March 31, 2026, reserves were $11.5 million and premiums received totaled $19.5 million.
Research Frontiers received two Nasdaq deficiency letters on June 2, 2026, saying its stock has closed below the $1.00 minimum bid price and its market value of listed securities has fallen below $35 million. The company has until November 30, 2026 to regain compliance, and the stock continues to trade on the Nasdaq Capital Market under REFR, but there is no assurance it will regain compliance.
Bid price notice: closing bid below $1.00 for 30 consecutive business days from April 15 to June 1, 2026
MVLS notice: market value of listed securities below $35 million for 30 consecutive business days from April 20 to June 1, 2026
Compliance deadline: November 30, 2026; regaining compliance requires ten consecutive business days at or above the thresholds
The company does not currently intend to effect a reverse stock split to regain compliance
Black Rifle Coffee said the NYSE confirmed it regained compliance with the $1.00 minimum share price standard, as of May 29, 2026, based on that day's closing price and a 30 trading-day average. The company said this happened without the reverse stock split that stockholders approved at the May 28, 2026 annual meeting, and its Class A stock will continue to trade on the NYSE.
NYSE notified the company on June 1, 2026 that it regained compliance as of May 29, 2026.
The company had received a non-compliance notice on February 11, 2026, after its 30 trading-day average closing price fell below $1.00.
Stockholders approved a reverse split authority of 1-for-10 to 1-for-50 with 78,970,591 For and 7,235,842 Against votes from Class A holders.
At the May 28, 2026 annual meeting, 145,942,807 of 249,125,057 eligible shares were represented, and Ernst & Young LLP was ratified for fiscal 2026 with 144,256,280 For votes.
Exicure received a Nasdaq notice on May 28, 2026 that it was not in compliance with Listing Rule 5250(c)(1) because its quarterly report for the period ended March 31, 2026 was late. The company filed the Form 10-Q on May 29, 2026 and believes it has regained compliance, attributing the delay to changes in its financial reporting personnel and filing procedures.
Nasdaq notice received May 28, 2026 under Listing Rule 5250(c)(1) for late 10-Q filing
Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 29, 2026
Company attributes the delay to changes in financial reporting personnel and related filing procedures
Company believes it has regained compliance with the Nasdaq rule
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.